Down-under medtech firm Admedus looks to future in bio-scaffolds

Australian med-tech company Admedus (ASX:AHZ) is looking to become the “gold standard” in cardiac bio-scaffolds and expand their product into other realms to promote rebuilding of tissue over artificial replacements. Admedus COO Julian Chick spoke to MassDevice.com yesterday about the company’s flagship product CardioCel, how its using bio-scaffolds to grow in the cardiac repair market and where it’s looking to take the bio-scaffolds next. Admedus’ CardioCel bio-scaffolds are regenerative tissue patches designed for cardiac and vascular repairs and reconstructions and promote autologous growth, Chick said. “It’s taken about 11 years to get where we are today. The basis of it was – a group of bioengineers and cardiologists had gotten together to discuss existing tissues on the market, and they all had problems. They had calcification issues, rejection problems, scarring and etc. And they thought how can we adapt that manufacturing process to produce a tissue that doesn’t go through that,” Chick told MassDevice.com in an interview. The net result was the creation of the Adapt process, which Admedus uses to produce the CardioCel bio-scaffolds, Chick explained. The company’s 1st forays with the scaffolds were in the pediatric realm in patients with congenital heart problems, Chick said. “We went into pediatrics and did a phase 2 study prior to approval.  The product was used in 30 cases in pediatric cases from...
Source: Mass Device - Category: Medical Equipment Authors: Tags: Cardiovascular Implants Regenerative Medicine Admedus Ltd. Source Type: news